drugset / Trial / NCT06553547
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
Timeline
- Start
- 2024-07-24
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenapanor | Small molecule | 2 mg | — |
| Subject | Tenapanor | Small molecule | 5 mg | — |
| Subject | Tenapanor | Small molecule | 10 mg | — |
| Subject | Tenapanor | Small molecule | 15 mg | — |
| Subject | Tenapanor | Small molecule | 20 mg | — |
| Subject | Tenapanor | Small molecule | 25 mg | — |